What alternative medication can be used instead of brensocatib (Brinsupri) for non‑cystic fibrosis bronchiectasis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Alternative Medications for Brinsupri (Brensocatib) in Non-Cystic Fibrosis Bronchiectasis

For patients unable to take brensocatib, the primary alternatives are long-term macrolide antibiotics (azithromycin or erythromycin) or inhaled antibiotics, with the specific choice depending on whether the patient has chronic Pseudomonas aeruginosa infection.

Treatment Algorithm Based on Pathogen Status

For Patients WITH Chronic P. aeruginosa Infection:

First-line alternative: Inhaled colistin 1 MU twice daily delivered through I-neb 1

  • This is the preferred inhaled antibiotic with Grade B recommendation
  • Extends time to exacerbation and improves quality of life

Second-line alternative: Inhaled gentamicin 1

  • Consider if colistin is not tolerated
  • Increases time to exacerbation and reduces exacerbation rate
  • Important safety precautions:
    • Avoid if creatinine clearance <30 mL/min
    • Use caution with significant hearing loss or balance issues
    • Avoid concomitant nephrotoxic medications

Third-line alternative: Azithromycin or erythromycin 1, 2

  • Use if patient cannot tolerate inhaled antibiotics
  • Can also be added to inhaled antibiotics for high exacerbation frequency
  • Azithromycin dosing: Start with 250 mg three times weekly, increase based on response 1
  • Erythromycin: 400 mg twice daily 2

For Patients WITHOUT P. aeruginosa Infection:

First-line alternative: Long-term macrolides 1, 2

  • Azithromycin or erythromycin
  • Reduce exacerbation number with Grade 1++ evidence
  • Critical safety requirements before starting:
    • Ensure at least one negative respiratory NTM (non-tuberculous mycobacterial) culture
    • Use caution with significant hearing loss or balance issues

Second-line alternative: Long-term oral targeted antibiotic based on sputum culture 1

  • Only if macrolides contraindicated, not tolerated, or ineffective
  • Must be guided by antibiotic susceptibility testing

Third-line alternative: Long-term inhaled antibiotic 1

  • Consider if oral antibiotics are contraindicated, not tolerated, or ineffective

Critical Implementation Points

Patient Selection Criteria:

All alternatives should be considered for patients with ≥3 exacerbations per year despite optimized management 1, 3. The 2026 American College of Chest Physicians guideline specifically recommends long-term macrolides and brensocatib with conditional recommendation and moderate certainty evidence 3.

Before Starting Any Long-Term Antibiotic:

  1. Review culture and mycobacterial status
  2. Optimize airway clearance techniques
  3. Treat other associated conditions
  4. Ensure respiratory specialist involvement 1

Monitoring Requirements:

  • Review patients every 6 months for efficacy, toxicity, and continuing need 1
  • Monitor sputum culture and sensitivity regularly (though in vitro resistance may not affect clinical efficacy)
  • For macrolides: Regular NTM surveillance
  • For inhaled aminoglycosides: Renal function and audiometry

Comparative Efficacy Context

Recent network meta-analysis data shows that among antiinflammatory therapies, macrolides demonstrate the greatest reduction in exacerbation frequency (rate ratio 0.44,95% CI 0.35-0.56), while DPP-1 inhibitors like brensocatib show rate ratio 0.73 (95% CI 0.60-0.88) 4. Notably, DPP-1 inhibitors remain effective even in patients already on long-term macrolides, suggesting these mechanisms can be complementary 4.

Common Pitfalls to Avoid

  1. Do NOT use inhaled aztreonam - it has higher adverse events and no clinically significant benefit 1
  2. Do NOT routinely use non-macrolide oral antibiotics without clear evidence of specific pathogen and macrolide contraindication 5
  3. Do NOT use PDE4 inhibitors, methylxanthines, leukotriene receptor antagonists, CXCR2 antagonists, neutrophil elastase inhibitors, or statins for bronchiectasis treatment 1
  4. Perform bronchodilator challenge test before starting inhaled antibiotics to assess tolerance 1

Escalation Strategy

If patients continue to have ≥3 exacerbations per year despite Step 3 treatment, consider combining long-term macrolide with long-term inhaled antibiotic 1. For patients with ≥5 exacerbations per year despite maximal therapy, consider regular intravenous antibiotics every 2-3 months 1.

Related Questions

What are the dosing, monitoring requirements, side effects, and alternative treatments for brensocatib in adults with non‑cystic fibrosis bronchiectasis who have experienced at least two exacerbations in the prior year?
What is the recommended starting dose, monitoring schedule, contraindications, and pregnancy precautions for brensocatib (Brinsupri) in patients aged 12 years or older with non‑cystic fibrosis bronchiectasis?
Can brensocatib (Brinsupri) be added to Jascayd (azithromycin)?
What is the recommended management for bronchiectasis in a patient with diabetes, a past history of pulmonary tuberculosis, and recurrent childhood respiratory tract infections?
What are the effects and recommended administration of hypertonic saline nebulization (3‑7% saline, 4–5 mL, 2–3 times daily) for improving mucus clearance in patients with cystic fibrosis or bronchiectasis, including the need for pre‑treatment bronchodilator?
What is Phos‑Nak (sodium phosphate oral solution) used for?
What is the appropriate dosing regimen of metoprolol succinate for rate control in atrial fibrillation?
Why are Phosnak (oral sodium phosphate) and Klor‑Con (extended‑release potassium chloride) used together?
In a patient requiring a second-line Helicobacter pylori eradication regimen where rifabutin is unavailable, can the therapy be switched to an alternative regimen based on local antibiotic resistance patterns?
Can trauma be stored in muscle tissue?
In a hospitalized patient who refuses basal insulin (Lantus insulin glargine) and metformin, preferring rapid‑acting insulin (Humalog insulin lispro) with an 8‑unit pre‑meal dose and a medium‑dose correction scale, should we continue this regimen with close blood‑glucose monitoring or switch to an alternative regimen?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.